Guard Therapeutics International AB (SE:GUARD)
:GUARD
Want to see SE:GUARD full AI Analyst Report?
Top Page
Guard Therapeutics International AB
(GUARD)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr0.91
▼(-33.77% Downside)
Action:ReiteratedDate:04/23/26
The score is driven primarily by weak financial performance (no revenue, large ongoing losses, and heavy cash burn that has materially reduced equity/assets), which outweighs the benefit of having no debt. Technicals add pressure due to a clear downtrend (below key moving averages with negative MACD), while valuation metrics provide limited support given the negative P/E and no dividend yield data.
Positive Factors
Debt-Free Balance Sheet
A consistent absence of debt reduces refinancing and covenant risk, giving management strategic optionality to prioritize R&D or partnerships without near-term interest obligations. Over a 2–6 month horizon, being debt-free materially lowers forced financing pressure compared with leveraged peers.
Negative Factors
No Commercial Revenue
Sustained zero revenue means the business remains pre-commercial and fully dependent on external funding or partnerships to sustain operations. Over a 2–6 month horizon this elevates execution risk: without clear near-term commercialization or partner deals, funding needs may force dilution or strategic trade-offs.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
A consistent absence of debt reduces refinancing and covenant risk, giving management strategic optionality to prioritize R&D or partnerships without near-term interest obligations. Over a 2–6 month horizon, being debt-free materially lowers forced financing pressure compared with leveraged peers.
Read all positive factors
Guard Therapeutics International AB (GUARD) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr21.38M
Dividend YieldN/A
Average Volume (3M)44.15K
Price to Earnings (P/E)―
Beta (1Y)0.65
Revenue GrowthN/A
EPS Growth19.98%
CountrySE
Employees12
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.81
Shares Outstanding20,167,631
10 Day Avg. Volume59,609
30 Day Avg. Volume44,153
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.65
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.04
Revenue Forecast (FY)N/A
Guard Therapeutics International AB Business Overview & Revenue Model
Company Description
Guard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that preven...
How the Company Makes Money
null...
Guard Therapeutics International AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
35
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -15.00K | -15.00K | -15.00K |
| EBITDA | -123.13M | -107.74M | -100.23M | -114.91M | -112.82M | -82.01M |
| Net Income | -124.12M | -108.85M | -96.07M | -113.32M | -110.76M | -82.16M |
Balance Sheet | ||||||
| Total Assets | 101.87M | 54.14M | 55.74M | 85.23M | 202.60M | 190.44M |
| Cash, Cash Equivalents and Short-Term Investments | 100.48M | 49.83M | 54.19M | 83.74M | 201.01M | 188.60M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 21.47M | 13.51M | 17.77M | 18.49M | 25.24M | 14.66M |
| Stockholders Equity | 80.40M | 40.63M | 37.97M | 66.73M | 177.36M | 175.78M |
Cash Flow | ||||||
| Free Cash Flow | -116.98M | 0.00 | -94.75M | -116.05M | -102.14M | -77.59M |
| Operating Cash Flow | -116.98M | -109.35M | -94.75M | -116.05M | -102.14M | -77.59M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -1.00K | 0.00 |
| Financing Cash Flow | 126.37M | 107.22M | 62.66M | -779.00K | 112.60M | 176.30M |
Guard Therapeutics International AB Technical Analysis
Negative
1.38
Price Trends
1.52
Negative
1.55
Negative
9.80
Negative
Market Momentum
-0.09
Positive
38.85
Neutral
58.86
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GUARD, the sentiment is Negative. The current price of 1.38 is above the 20-day moving average (MA) of 1.36, below the 50-day MA of 1.52, and below the 200-day MA of 9.80, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 38.85 is Neutral, neither overbought nor oversold. The STOCH value of 58.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:GUARD.
Guard Therapeutics International AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | kr389.21M | -3.40 | -25.80% | ― | 70.42% | 67.58% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr226.66M | -44.78 | -16.90% | ― | -23.33% | ― | |
46 Neutral | kr419.44M | -27.57 | ― | ― | -21.73% | 43.11% | |
45 Neutral | kr314.13M | -1.89 | -16.51% | ― | ― | 18.65% | |
44 Neutral | kr380.61M | -4.79 | -79.60% | ― | ― | 48.34% | |
42 Neutral | kr21.38M | -0.24 | -186.13% | ― | ― | 19.98% |
* Healthcare Sector Average
SE:GUARD
Guard Therapeutics International AB
1.06
-12.94
-92.43%
SE:XBRANE
Xbrane Biopharma AB
11.00
-13.13
-54.40%
SE:ACE
Ascelia Pharma AB
3.00
-0.78
-20.63%
SE:IVACC
Intervacc AB
1.14
-0.02
-1.38%
SE:IMMU
Immunicum AB
5.13
-0.96
-15.76%
SE:CLBIO
Corline Biomedical AB
16.05
5.80
56.59%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.